Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Novacyt   /   Novacyt de volgende biotech raket!

Aandeel Novacyt PSE:ALNOV.FR, FR0010397232

Laatste koers (eur) Verschil Volume
0,662   +0,019   (+2,95%) Dagrange 0,649 - 0,687 431.648   Gem. (3M) 1,2M

Novacyt de volgende biotech raket!

Volgen
70.759 Posts
Pagina: «« 1 ... 2993 2994 2995 2996 2997 ... 3538 »» | Laatste | Omlaag ↓
  3. Erg chebbi 20 april 2021 07:19
    quote:

    Louis7 schreef op 19 april 2021 10:06:

    Biden administration invests $1.7 billion to fight COVID-19 variants.
    APRIL 18, 2021

    The U.S. is setting up a $1.7 billion national network to identify and track worrisome coronavirus mutations whose spread could trigger another pandemic wave, the Biden administration announced on Friday.

    www.cbsnews.com/news/biden-administra...
    "White House officials unveiled a strategy that features three components: a major funding boost for the Centers for Disease Control and Prevention and state health departments to ramp up coronavirus gene-mapping; the creation of six "centers of excellence" partnerships with universities to conduct research and develop technologies for gene-based surveillance of pathogens, and building a data system to better share and analyze information on emerging disease threats, so knowledge can be turned into action"

    Gene-mapping (als post pandemie-activiteit): Waar heb ik dat eerder gehoord?
  15. [verwijderd] 20 april 2021 09:13
    quote:

    voda schreef op 20 april 2021 09:03:

    Ik heb dat boekje juist laten zien (zo laat) dat de animo om nog dit aandeel te kopen compleet weg is.

    € 4,571 -0,04 (-0,95%)
    Geen nieuws of negatief nieuws - koers verder omlaag.
    positief nieuws , koers omhoog.

    Welke kans schat je het hoogste in , daar gaat het om , de markt heeft voorlopig een keuze gemaakt.
  17. forum rang 10 voda 20 april 2021 09:23
    quote:

    waarom niet schreef op 20 april 2021 09:13:

    [...]
    Geen nieuws of negatief nieuws - koers verder omlaag.
    positief nieuws , koers omhoog.

    Welke kans schat je het hoogste in , daar gaat het om , de markt heeft voorlopig een keuze gemaakt.

    Ik ben het met je eens. Binnenkort de 2020 cijfers? Ik weet het niet meer. Ik reken nog op een ge-update outlook. Zie de koers ook niet opeens omhoog schieten (zo als laatst met bijna 10%)
  18. kw1986 20 april 2021 09:26
    avacta.com/lft-clinical-validation/?u...

    20 Apr 2021
    Clinical validation of AffiDX® SARS-CoV-2 Antigen Lateral Flow Test
    98.0% clinical sensitivity for samples with PCR Ct values1 up to 31

    Completing the technical data set for self-declaration of a CE mark for professional use in early May, followed immediately by commercial launch in Europe

    Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce positive data from the clinical validation of its AffiDX® SARS-CoV-2 antigen lateral flow test. Data from the clinical study conducted in Europe on 98 positive COVID-19 samples demonstrate excellent performance in identifying the SARS-CoV-2 virus across a broad range of viral loads. These data will now be combined with stability and other performance data from ongoing studies to finalise the technical file for CE marking the AffiDX® SARS-CoV-2 antigen lateral flow test for professional use, allowing the Company to begin commercial roll-out in Europe in May.

    The clinical evaluation of Avacta’s lateral flow test was carried out at a single site in Europe with patient samples with viral loads confirmed by PCR. The study tested 98 positive samples (31 with Ct<26; 65 with Ct 26-30 and 2 with Ct 30-31). Avacta’s rapid antigen test identified 96/98 of these correctly as positive with a 20 minutes read time resulting in a clinical sensitivity of 98.0% for samples within this broad range down to low viral loads. Out of a total of 102 negative samples tested with the lateral flow device, the test correctly identified 101 as negative, giving a clinical specificity of 99.0%.

    Lateral flow rapid antigen tests are intended to provide a low cost means of identifying individuals with a high viral load that means they are more likely to infect others. Many factors affect whether an individual will infect others or not, as well as viral load, such as the circumstances and length of exposure. However, there is a growing consensus that a viral load as measured by PCR of Ct<27 should be considered as infectious. The clinical data for Avacta’s AffiDX® SARS-CoV-2 antigen lateral flow test demonstrated 100% sensitivity for identifying infectious individuals in this range.

    Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:

    “I am delighted with the clinical data from this larger clinical study, which has robustly evaluated the AffiDX® antigen test with lower viral loads of Ct>26 as well as with higher viral load samples. The results are very impressive and marks a major step in obtaining a CE mark for professional use.

    “As part of the study the same clinical samples were tested with two leading, commercially available lateral flow antigen tests, and the data show that the AffiDx® test had better clinical sensitivity across the range of Ct value and in particular at lower viral loads.

    “We are completing the necessary assessment of the product from our manufacturing partner Global Access Diagnostics, including stability testing that will complete the technical file for CE marking, which we expect will happen in early May.

    “We are very excited by the potential of this high quality SARS-CoV-2 rapid antigen test and we are looking forward to updating the market as we commercially roll-out the AffiDX® test in the coming months.”

    This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

    Disclaimer: The AffiDX® SARS-Cov-2 rapid antigen test is not currently available for sale in the United States.

    [1] Ct or cycle time indicates the number of cycles of amplification required before the virus gene can be detected by PCR. The higher the Ct value the more amplification that was needed to identify the virus in the sample, and therefore the lower the amount of virus present. Conversely, a high viral load means that there is more virus present and fewer amplification cycles are required to detect it mean a lower Ct value is returned.
70.759 Posts
Pagina: «« 1 ... 2993 2994 2995 2996 2997 ... 3538 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee